- Monoclonal antibody targeting type I interferon (IFN-I) receptor (IFNAR1)
- Indicated for systemic lupus erythematosus
- Adverse effects include:
- Upper respiratory tract infection
- Nasopharyngitis
- Infusion-related reaction
- Bronchitis
- Urinary tract infection
- Sinusitis
- Increased risk of herpes zoster
